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The syndrome of inappropriate antidiuretic hormone (SIADH) consists of a number of key features, 
namely hyponatraemia, inappropriate urinary concentration and clinical euvolaemia or 
hypervolaemia. It is caused by inappropriate secretion of the antidiuretic hormone (ADH), which 
activates the vasopressin type 2 receptor (AVPR2) in the principal cells of the collecting duct of the 
kidney and leads to increased reabsorption of water through aquaporin 2 channels. Common causes of 
SIADH in children include trauma, asphyxia, pain, stress, certain drugs and recent neurosurgery (1). 
The first line of therapy is simply fluid restriction (1). Unfortunately, this is often unsuccessful in 
patients with free access to fluids and thirst is reportedly increased in SIADH (2). Moreover, it is not 
feasible for infants for prolonged periods of time, as their caloric intake is directly coupled to milk 
and thus fluid intake and fluid restriction would lead to starvation. A simple treatment option is the 
so-called vaptans, which are specific antagonists of the AVPR2 receptor, with tolvaptan providing an 
orally active form (3). While tolvaptan has not yet been formally assessed in children, we previously 
reported its successful use in two infants with chronic SIADH in Acta Paediatrica (4). A drawback to 
long-term tolvaptan use is cost, namely £896 for 10 tablets of 15mg each in the UK, and the potential 
for liver function abnormalities (5). An alternative treatment option is urea, which leads to osmotic 
diuresis (6). Urea is a key constituent of the so-called osmotic load, which are the solutes that need to 
be cleared by the kidney and thus obligate accompanying water excretion (7). The main disadvantage 
of urea supplementation is its foul taste, although mixing it with citrate has been reported to result in 
better acceptance by patients (8). Here we report on the successful use of urea treatment in our 
previously reported child with chronic SIADH (4) at the age of 16 months. The boy has a congenital 
form of chronic SIADH associated with an ectopic posterior pituitary. He had been successfully 
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treated with tolvaptan for approximately one year, but alternative treatments were considered due to 
concerns about the cost and potential liver injury, due to borderline elevated aspartate transaminase 
(AST), with a maximum of 74IU/l being recorded and an upper limit of normal of 67IU/l. All other 
liver function tests remained normal throughout. Urea was obtained in the form of sachets containing 
15g (16.7mmol) of urea mixed with citric acid and flavourings (Nutricion Medica, Spain: 
www.nutricionmedica.com). 
 
 He was electively admitted at the age of 15 months so that his treatment could be converted 
from tolvaptan to urea. The pertinent data are given in Table 1. First we established the persistence of 
SIADH by withdrawing tolvaptan, which led to a recurrence of hyponatraemia (126mmol/l) within 
two days. Urea was initially commenced at 1g/kg/day, divided into two doses. There was a small 
increase in plasma sodium to 128mmol/l after two doses and to 129mmol/l after a total of four doses. 
The frequency of dosing was subsequently increased to three times a day, providing a total of 
1.5g/kg/day. The following day, after three doses, the boy’s plasma sodium had increased to 
136mmol/l. Initially, the patient had difficulties in tolerating the urea and vomited after every dose, 
but this improved when we minimised the volume in which the contents of the sachets were 
dissolved. The parents eventually identified a way to make it palatable for him by dissolving the 
contents of the sachet in 5ml of fruit puree, instead of the 100ml of water recommended by the 
manufacturer. They then split the resultant volume, of approximately 20ml, into four doses. Since the 
start of urea treatment, our patient has remained well. As expected, his plasma urea level has 
increased from around 1-5mmol/l on tolvaptan to 8-10mmol/l with urea supplementation. His plasma 
creatinine has remained unchanged, at around 20mol/l. 
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Urea has been extensively described as an inexpensive and safe treatment option for adults with 
chronic SIADH (9). A prospective long-term study showed similar efficacy for urea and vaptans in 
the long-term treatment of hyponatraemia secondary to SIADH (6). Within the peadiatric population, 
its effectiveness has only been detailed in case reports (10, 11). However, those studies seem 
promising and also reported the successful treatment of hyponatraemia in children with chronic 
SIADH.  
The reported difficulties in taking urea due to its unpalatable taste and potential purgative effects were 
also clearly observed in our patient, even though the formulation that was provided was already mixed 
with citrate and flavourings. Nevertheless, with persistence and some experimentation with the 
preparation, the patient learned to accept the supplementation and now tolerates it without any 
difficulties. Based on the current dose of urea, his annual treatment cost is approximately £500, which 
compares favourably to tolvaptan, at £16,350 per year. The tolvaptan cost had already been reduced 
by splitting the 15mg tablet in half to provide dosing for two days, a process not recommended by the 
manufacturer. Using a new tablet each day would obviously have doubled the cost to £32,700 per 
year. 
An alternative to urea and tolvaptan would have been no treatment at all and to just accept 
hyponatraemia. We had repeatedly stopped tolvaptan treatment to assess for ongoing SIADH in this 
patient. Each time, his plasma sodium settled around 126-130 mmol/l. Chronic hyponatraemia in 
adults has been associated with impaired psychomotor function (12)) and even osteoporosis (13). 
Obviously, this is difficult to assess in infants, but neither the parents nor the medical personnel noted 
an apparent difference in the child’s behaviour when he was hyponatraemic. Some patients may have 
a better tolerance for hyponatraemia and we previously reported the case of a London taxi driver, who 
had no apparent dysfunction despite presumably having lifelong hyponatraemia (14). Given the 
inexpensive and benign treatment we have achieved with urea, we have opted to continue with this for 
the time being. 
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In conclusion, this case study shows how we achieved successful treatment of chronic hyponatraemia 
with urea in an infant. Urea should be considered as an alternative and inexpensive treatment option 
to vaptans in children with chronic SIADH.  
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Table 1 Pertinent clinical data 
 
Timeline On tolvaptan Two days off 
tolvaptan 
Urea x 1day Urea x 3days Urea x 1month 
Age (months) 9 15 15 15 16 
Treatment Tolvaptan 
0.2mg/kg/day 
Tolvaptan 
off 
Urea 
1g/kg/day 
Urea 
1.5g/kg/day 
 
Urea 
1.5g/kg/day 
 
Weight (g) 6,050 8,100 8,100 8,000 8,150 
Plasma 
   Sodium (mmol/l) 
Osmolality (mosmol/kg) 
  Urea (mmol/l) 
 
136 
ND 
1.1 
 
126 
257 
5.2 
 
128 
270 
10.2 
 
136 
277 
8.5 
 
136 
277 
9.3 
Urine 
   Sodium (mmol/l) 
Osmolality (mosmol/kg) 
 
<5 
61 
 
96 
541 
 
15 
618 
 
10 
853 
 
14 
835 
 
Note recurrence of hyponatraemia after withdrawal of tolvaptan, associated with increased urine 
osmolality, reflecting persistent SIADH. Plasma sodium levels normalised again with urea 
supplementation. ND: not determined. 
 
 
 
